JOHN M.C. CONNELL, M.B.; DOUGLAS C. MCCRUDEN, B.SC.; D.L. DAVIES, M.D.; W. DONALD ALEXANDER, M.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: In the concluding paragraphs of the National Institutes of Health conference on inappropriate thyroid stimulating hormone (TSH) secretion, somatostatin or dopamine analogues were suggested as possible appropriate therapies in this condition (1). We write to report preliminary results of use of the dopamine agonist bromocriptine (Parlodel, Sandoz, Ltd, London, United Kingdom) in this condition.
A 56-year-old white man presented with thyrotoxicosis in 1978, with an elevated serum free thyroxine (T4) of 164 nmol/L (normal range, 55 to 144 nmol/L); free triiodothyroxine (T3), 3 nmol/L (normal range, 0.9 to 2.8 nmol/L); and early (20 minutes) iodine uptake, 25%
CONNELL JM, MCCRUDEN DC, DAVIES D, et al. Bromocriptine for Inappropriate Thyrotropin Secretion. Ann Intern Med. 1982;96:251–252. doi: https://doi.org/10.7326/0003-4819-96-2-251
Download citation file:
Published: Ann Intern Med. 1982;96(2):251-252.
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use